tbuckley/cabot-search huggingface dataset:
SAT0005 Sle Patients in Emergency. the Evaluation of SLE Patients in Helsinki University Central Hospital Emergency during 2003-2012
Authors: J. Tolonen, A. Häme, N. Forss, V.-P. Harjola, R. Luosujärvi, J. Mattila
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic lupus erytematosus (SLE) is more common in women (∼90% of SLE-patients) and in ∼50% of the patients was the diagnosis set ≤30 y age. The neurological symptoms are not seenvery frequently, but these may be difficult to relate in SLE, especially in emergency (ED). <h3>Objectives</h3> The aim of this study was to analyze the proportion of neurological SLE patients in a tertiary University Hospital ED 2003-2012. <h3>Methods</h3> We used Helsinki University Central Hospital Meilahti ED electrical database retrospectively. We search all the patients with the SLE diagnosis. The ED visit was interpreted as neurological if the charge for the treatment was allocated for neurologist. We analyzed also the need for the spinal fluid examination in ED. Data was compared statistically by Students9 T test for continous parameters and by Mann-Whitney U Test for noncontinous ones. The point for statistical significance was set at p&lt;0.05. <h3>Results</h3> 44 SLE patients (male7) made 254 visits in ED 2003-2012. 33% of visits (n=84) were related to SLE. 19% of visits (n=48) were classified as neurological, and 67% of these (n=32) were SLE-related. Spinal fluid examination in ED was needed in 6 visits; 1 bacterial meningitis, 1 septicaemia, 1 tetraparesis, 1 disorientation, 1 hemiparesis and 1 SLE-associated muscle disease. Female SLE patients (mean 6.2) visited almost twice as many times in ER than male ones (mean 3.7). Moreover thirteen female visited ≥7 times in ED as compared to one male. The difference between genders was not, however, significant, p=0.570 and p=0.850, respectively. Indeed SLE-patients with neurological symptoms visited in ED significantly more often than those without (p=0.007). <h3>Conclusions</h3> SLE was not extremely common diagnosis in our ED. Female SLE patients were overrepresented. In 2/3 patients with neurological symptoms seemed these to be SLE-related. SLE-patients with neurological symptoms visited more often in ED than those without. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2234
SUPERIORITY OF THE NEW ACC / AHA 2013 RISK SCORE OVER THE TRADITIONAL FRAMINGHAM SCORE IN PREDICTING MORTALITY IN A HEALTHY POPULATION IN CHILE
Authors: Monica Acevedo, Veronica Kramer, Giovanna Valentino, Lorena Orellana, Maria Jose Bustamante, Marcela Adasme, Alejandra Salazar, Carlos Navarrete
Journal: Journal of the American College of Cardiology (2015)
Prospective Study of Asymmetric Retinopathy as a Predictor of Brain Infarction in Diabetes Mellitus
Authors: Kenzo Iino, Mototaka Yoshinari, Koichiro Kaku, Misao Yamamoto, Yuichi Sato, Tomoyuki Kodama, Masanori Iwase, Masatoshi Fujishima
Journal: Diabetes Care (1993)
Abstract 1629: Restoration of the wild type function to mutant p53 by chemopreventive agent phenethyl isothiocyanate
Authors: Xiantao Wang, Sudha Govind, Jessie Yu-Chieh Wu, York Tomita, Lixin Mi, Anthony J. Di Pasqua, Fung-Lung Chung
Journal: Cancer Research (2010)

Abstract p53 mutations occur in more than 50% of all human tumor. Mutant p53 is incapable of activating downstream target genes necessary for cell cycle arrest and apoptosis. Phenethyl isothiocyanate (PEITC), a cruciferous vegetable-derived compound, has been shown to possess anti-cancer property by causing cell growth arrest or apoptosis in tumor cell lines and animal models. Recently, we have found that PEITC can selectively reduce mutant p53, but not wild type protein levels in a variety of tumor cell lines. Here, we demonstrate that PEITC can increase sequence specific DNA binding of p53 in NSCLC H596 cells expressing mutant p53 and induce the expression of p53-dependent target proteins, such as p21 and Noxa. Similar effects were observed in human glioblastoma T98G cells which also express mutant p53. H596 cells incubated with sulforaphane (SFN), another widely studied ITC compound with much weaker cytotoxicity, showed no increased specific DNA binding of p53. In addition, PEITC induced p53-responsive p21 and Noxa promoter luciferase activity. Blocking mutant p53 protein expression with shRNA in T98G cells entirely prevented p21 protein induction triggered by PEITC. Immunoprecipitation studies with conformation-specific p53 antibodies (Pab1620 and Pab240) show that treatment with PEITC alters mutant p53 to wild type conformation in H596 cells. Currently, we are investigating the significance of function restoration to mutant p53 by phenethyl isothiocyanate in the regulation of apoptosis by PEITC or other conventional chemotherapeutic drugs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1629.
A9.10 Synovial activation drives anti-inflammatory effects of adipose-derived stem cells after local administration in experimental oa which is reflected by s100a8/a9 levels in the serum
Authors: P L E M van Lent, R F Schelbergen, S van Daalen, M C ter Huurne, A B Blom, J Roth, T Vogl, C Jorgensen, W B van den Berg
Journal: Annals of the Rheumatic Diseases (2014)

Backgound and Objectives Synovitis is evident in a substantial subpopulation of patients with early osteoarthritis (OA) and has been associated with development of pathophysiology. Recently we have shown that adipose-derived stem cells (ASC) inhibit joint destruction after local application to knee joints with experimental OA. In the current study we explored the effect of synovitis on the immunomodulatory capacity of ASCs after local administration in two experimental OA models differing in synovitis. Material and Methods ASCs were isolated from fat surrounding the popliteal lymph nodes. ASCs were injected into knee joints after induction of collagenase-induced OA (CiOA) characterised by synovitis and surgically induced DMM model in which synovitis is scant. Synovial activation, chondrogenesis in ligaments and osteophytes were measured using histology. Cytokines in synovial washouts and serum were determined using Luminex. Active TGFβ was measured using the CAGAluc assay. Results ASCs injected into knee joints at different time-points after induction of DMM (day 7, day 14 or day 7 and day 14) had no effect on development of ligament damage or osteophyte formation. In contrast, ASC treatment of collagenase-induced OA knee joints, rapidly inhibited synovitis and ligament damage when administered at day 7 after induction. Washouts of synovium taken at different time points after injection of ASCs (6 hrs, day 2, day 14 and day 42) showed significantly decreased levels of IL-1β and S100A8/A9 already at 48 hrs after ASC treatment. No effect was found on levels of active TGFβ. Serum levels of S100A8/A9 were significantly decreased (85% lower) at day 14 whereas IL-1 levels were not detectable at that time-point. Next, we explored the effect in CiOA in a condition with less synovial inflammation. Synovial thickness at day 42 was 62% lower when compared to the former study. Injection of the same dose of ASCs at day 7 after induction of CiOA, only marginally inhibited synovial thickening when measured at day 42. Serum levels of S100A8/A9 were low at day 14 (around 50 ng/ml compared to 800 ng/ml in the first experiment) and were not altered by the ASC treatment. Chondrogenesis in collateral and cruciate ligaments but also osteophyte formation at the bone margins was also not diminished. Conclusion Our study indicates that synovial activation rapidly drives anti-inflammatory effects of ASCs after local administration in murine OA knee joints with synovitis protecting against development of ligament damage and osteophyte formation.
Abstract 1753: KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells <i>in vitro</i>.
Authors: Hanna E. Rauhala, Eeva Laurila, Elisa Vuorinen, Kimmo Savinainen, Anne Kallioniemi
Journal: Cancer Research (2013)

Abstract Pancreatic cancer is an aggressive malignancy and one of the leading causes of cancer deaths. The high mortality rate is mostly due to the lack of appropriate tools for the early detection of the disease and a shortage of effective therapies. We have previously shown that karyopherin alpha 7 (KPNA7) is frequently amplified and overexpressed in pancreatic cancer. KPNA7 is a recently characterized member of the alpha karyopherin family of nuclear import receptors. The nuclear import machinery is composed of a complex network of proteins required for the appropriate transport of proteins from the cytoplasm to the nucleus. Abnormal function of this machinery leads to incorrect localization of nuclear proteins and disturbances in cellular homeostasis, which may subsequently contribute to the development of various diseases including cancer. Indeed, previous evidence has linked members of the karyopherin alpha family, especially KPNA2, to cancer pathogenesis. In this study we demonstrate that KPNA7 expression is absent in practically all normal human adult tissues but elevated in several pancreatic cancer cell lines as well as in some other cancer types. Inhibition of KPNA7 expression in AsPC-1 and Hs700T pancreatic cancer cells led to a striking reduction in cell growth due to the induction of the cell cycle regulator p21 and subsequent G1 arrest of the cell cycle. In both of these cell lines KPNA7 silencing also resulted in decreased anchorage independent growth, and additionally in the AsPC-1 cells reduced cell migration and invasion. Furthermore, in the Hs700T cells KPNA7 silencing resulted in dramatic morphological change where the cells acquired fibroblast-like shape. This phenotypic change was not explained by induction of EMT or senescence. In conclusion, our data strongly demonstrate that KPNA7 silencing inhibits the malignant properties of pancreatic cancer cells in vitro and thereby provide the first evidence on the functional role of KPNA7 in human cancer. Moreover, the lack of KPNA7 expression in normal adult tissues highlights it as a potential novel therapeutic target for cancer. Further studies are needed to identify the cargo proteins transported by KPNA7. These studies are likely to reveal important new information on nuclear transport and may highlight the molecular mechanisms involved in KPNA7 mediated phenotypes in cancer cells. Citation Format: Hanna E. Rauhala, Eeva Laurila, Elisa Vuorinen, Kimmo Savinainen, Anne Kallioniemi. KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1753. doi:10.1158/1538-7445.AM2013-1753
Abstract 89: Prostaglandin E2 promotes intestinal tumor growth via DNA methylation
Authors: Dianren Xia, Dingzhi Wang, Sun-Hee Kim, Raymond N. DuBois
Journal: Cancer Research (2011)

Abstract Evidence for the link between inflammation and cancer comes from epidemiologic and clinical studies showing that use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the relative risk for developing colorectal cancer (CRC) by 40-50%. NSAIDs exert some of their anti-inflammatory and anti-tumor effects by targeting cyclooxygenase enzymes (COX-1 and COX-2). COX-2-derived prostaglandin E2 (PGE2) is a pro-inflammatory mediator and promotes tumor progression. Clearly, DNA methylation is one of the critical mechanisms for silencing tumor suppressors and DNA repair genes during CRC initiation and progression. It has been demonstrated that a unique subset of CRC patients with extensive CpG island hypermethylation has unique clinicopathologic features and an exceedingly poor survival. However, all of the mechanisms by which chronic inflammation contributes to carcinogenesis are not understood and the precise role of aberrant DNA methylation in cancer also remains unclear. Here we used colorectal cancer cells to show that PGE2 treatment upregulated the expression of DNA methyltransferase 1 (DNMT1) and 3B (DNMT3B), which resulted to increased DNA methylation in the promoters of target genes O6-methylguanine-DNA methyltransferase (MGMT) and cannabinoid receptor 1 (CB1). Meanwhile, the expression of MGMT and CB1 were decreased. In ApcMin/+ mice, PGE2 treatment also increased the expression of DNMT1 and DNMT3B and the DNA methylation of MGMT and CB1 promoters, and reduced the expression of MGMT and CB1. All these alterations were accompanied by increases in both polyp number and size in the intestines of ApcMin/+ mice. More intriguingly, a combined treatment with a selective COX-2 inhibitor (celecoxib) and a demethylating agent (5-Aza-dC) significantly further reduced the polyp number and size in ApcMin/+ mice in comparison with single agent treatment. These results suggest that PGE2 can silence tumor suppressors and DNA repair genes via DNA methylation to promote tumor formation and progression. These findings uncover a previously unrecognized role for PGE2 promotion of tumor formation and progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 89. doi:10.1158/1538-7445.AM2011-89
Abstract 4325: Localization and expression of osteopontin in a chitosan-treated ovarian cancer cell line, SKOV-3
Authors: E. Gloria C. Regisford, Julia M. Stone, Laura E. Carson, Cordella Kelly-Brown, Pasakorn Traisawatwong, Antoine Hicks
Journal: Cancer Research (2011)

Abstract Ovarian cancer is the deadliest gynecological malignancy and despite current treatments, such as chemotherapy and radiotherapy, reoccurrence of this deadly malignancy is high. Although elevated levels of osteopontin (OPN), a phosphorylated glycoprotein, are always present in the ovaries, recent studies have implicated osteopontin (OPN) protein as a novel biomarker for ovarian cancer. Early detection of ovarian cancer is imperative, and furthermore, novel treatments with fewer adverse effects than current treatments of chemotherapy and radiation, are currently being investigated. Chitosan, a natural polysaccharide that is biodegradable and biocompatible, may serve as a potential alternative treatment for ovarian cancer, and may function by regulating OPN expression. Therefore, the objective of this study was to determine the effects of chitosan on the expression and localization of OPN in SKOV-3 cells. It was hypothesized that the expression of OPN protein will be down-regulated in a dose-dependent manner. To test this hypothesis, SKOV-3 cells were treated with 0, 50, 100, 250, and 500, ng/mL of chitosan for 48 hours. An MTT assay was performed to determine cell viability and proliferation rate. Cells were harvested; total protein was isolated and then subjected to SDS-PAGE and Western blot analysis. The localization of OPN was determined using immunocytochemistry, after chitosan treatment of SKOV-3 cells on two-chamber slides for 48 hours. The expression of OPN decreased in SKOV-3 cells in a dose-dependent manner. In addition, cell proliferation tended to decrease with increasing dose of chitosan. These data indicate that chitosan may inhibit SKOV-3 cell proliferation by decreasing OPN production and secretion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4325. doi:10.1158/1538-7445.AM2011-4325
Pulmonary Embolism after Ligation of the Inferior Vena Cava
Authors: Victor Gurewich, Duncan P. Thomas, Keith R. Rabinov
Journal: New England Journal of Medicine (1966)

THE rationale for venous ligation in pulmonary embolic disease is based on its assumed ability to prevent subsequent emboli from reaching the lungs. The level of the inferior vena cava is now generally accepted as the site of choice for ligation since anatomically its effectiveness appears assured. Recurrence of pulmonary embolism after this procedure is believed to be rare.1 2 3 This paper reports the findings in 9 patients with apparent pulmonary emboli that followed ligation suggesting that, contrary to current opinion, there is a significant recurrence rate. These patients, who were encountered over a period of two and a half years . . .
Endoscopic ultrasound-guided transgastric pancreatic duct drainage after Whipple surgery in a patient with chronic pancreatitis
Authors: C. Sun, Z.-D. Jin, X. Pan, D. Wang, Z.-S. Li
Journal: Endoscopy (2011)

A 34-year-old Chinese man was admitted for repeated episodes of diarrhea and abdominal pain following a Whipple procedure for a duodenal stromal tumor. Computed tomography (CT; [Fig. 1]) and magnetic resonance cholangiopancreatography (MRCP) were performed and revealed a severely dilated pancreatic duct after the procedure.
Geographic Variations in Utilization Rates in Veterans Affairs Hospitals and Clinics
Authors: Carol M. Ashton, Nancy J. Petersen, Julianne Souchek, Terri J. Menke, Hong-Jen Yu, Kenneth Pietz, Marsha L. Eigenbrodt, Galen Barbour, Kenneth W. Kizer, Nelda P. Wray
Journal: New England Journal of Medicine (1999)

In the United States, geographic variation in hospital use is common. It is uncertain whether there are similar geographic variations in the health care system of the Department of Veterans Affairs (VA), which differs from the private sector because it predominantly serves men with annual incomes below $20,000, has a central system of administration, and uses salaried physicians. Thus, it might be less likely to have geographic variations.
A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents
Authors: Albert Schömig, Franz-Josef Neumann, Adnan Kastrati, Helmut Schühlen, Rudolf Blasini, Martin Hadamitzky, Hanna Walter, Eva-Maria Zitzmann-Roth, Gert Richardt, Eckhard Alt, Claus Schmitt, Kurt Ulm
Journal: New England Journal of Medicine (1996)

The clinical benefit of coronary-artery stenting performed in conjunction with coronary angioplasty is limited by the risk of thrombotic occlusion of the stent as well as hemorrhagic and vascular complications of intensive anticoagulation. We compared antiplatelet therapy with conventional anticoagulant therapy with respect to clinical outcomes 30 days after coronary-artery stenting.
Complex statistical techniques cannot overcome weak methodology in the evaluation of breast cancer mortality trends
Authors: Eugenio Paci, Robert Smith, Mireille Broeders, Stephen Duffy
Journal: Journal of the Royal Society of Medicine (2013)

While underlying cause of death is the result of a standardized coding process, the mention of breast cancer as a cause of death, as used by Mukhtar et al.1 is not. Further, due to lead time, it increases the numbers of women ‘dying’ from breast cancer, especially in older women, who are more likely to die of other causes.
Refractory Anemia with Abnormal Iron Metabolism
Authors: Stanley L. Lee, Fred Rosner, Isaac Rivero, Felix Feldman, Alfred Hurwitz
Journal: New England Journal of Medicine (1965)

MEDIASTINAL-lymph-node hyperplasia resembling thymoma was first recognized as an entity by Castleman in 1954,1 although 3 cases of "enlarged inflammatory lymph nodes" had previously been described in 1946,2 in a series of 109 patients operated on for mediastinal tumors. Subsequently, Castleman, Iverson and Pardo Menendez3 presented a series of 13 cases, including 2 that had previously been classified as thymoma.4 , 5 The characteristic pathological features noted were germinal-center formation and marked capillary endothelial proliferation. These findings were consistent with hyperplasia and not neoplasia. Many similar cases have been reported.6 7 8 9 10 11 12 13 14 15 16 In none of the approximately 30 cases in the world literature was . . .
Abstract P5-10-14: Adjuvant Chemotherapy Treatment of Breast Cancer in Women 75 Years and Older
Authors: HG Kaplan, JA Malmgren, MK. Atwood
Journal: Cancer Research (2010)

Abstract Background: Adjuvant chemotherapy is not generally recommended for women 75 years and over due to presence of comorbid conditions and lower stage. Methods: We conducted a prospective cohort study of all women presenting with primary breast cancer (BC), aged 21-94, biopsy confirmed Stage 0-IV from 1990-2008 identified and tracked by our registry (n=8295). Clinical presentation characteristics including age, race, TNM stage, histologic type, surgical procedure, radiation and chemotherapy treatment were chart abstracted at diagnosis and follow up. Forward conditional stepwise regression was used to test for association significance for chemotherapy and the Kaplan-Meier method for disease free survival rate comparisons (DFS). Results: Women aged 75+ represented 12% of patients in our community based cancer center registry database (n=962). No change in percentage of patients aged 75+ was seen over time. The majority of 75+ BC patients were stage 0-1 (63%) with 36% stage II-III (n=339). Initial patient treatment was 74% lumpectomy/radiation (n=708), 11% mastectomy/radiation, and 11 % mastectomy/no radiation. 82% were estrogen receptor positive and of these 76% were recommended treatment with hormone therapy. 70% of patients received an oncology consult and 8% (n=76) were recommended for chemotherapy. Of the 76 patients, 59 (78%) completed chemotherapy with incompletions due to complications of therapy (10), patient choice (4), unknown (1), other reason (1), and death (1). The most commonly given chemotherapy regimens were CMF (n=21), AC/Taxol (n=13), and AC (n=7) with 13 receiving an adriamycin containing regimen and 22 receiving non-standard therapy. In a conditional logistic regression model of TNM stage I-IV 75+ patients (n=847) with outcome=adjuvant chemotherapy, significant variables by order of entry into the model were 1) TNM stage, 2) Her2/neu status, 3) estrogen receptor status and 4) age at diagnosis. Chemotherapy treatment rates for 50-59 year olds were 51%, 60-64 = 40%, 65-69 = 28%, 70-74 = 19%, and 75+ = 8% (Pearson chi square = 687.78, p&amp;lt;.001). DFS was equivalent for 75+ stage 0-I BC patients compared to 50-74 year olds, with a lower DFS rate among 75+ stage II-III patients (stage II: log rank test=10.21, p=.001, stage III: log rank test=4.14, p=.042). Conclusions: TNM stage was the predominant factor in deciding to treat patients 75+ with adjuvant chemotherapy. Stage 0-I patients age 75+ and 50-74 had equivalent survival. Stage II-III age 75+ patients had significantly worse DFS than age 50-74 patients. There is an urgent need to identify effective and tolerable treatment regimens for stage II-II BC patients 75 years and older. Figures available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-10-14.
Acute Hypotension Treated Successfully with Hydrocortisone
Authors: Henry A. Shenkin
Journal: New England Journal of Medicine (1961)

ACUTE adrenal crisis precipitated by stress superimposed upon chronic adrenal insufficiency has now become well recognized. Similarly, it is well appreciated that patients on long-term cortisone therapy for reasons other than adrenal insufficiency can be precipitated into acute adrenal failure by sudden withdrawal of hormone therapy or by superimposition of stress without a corresponding increase in steroid therapy. Less frequently reported but nevertheless well understood is the fact that severe stress such as extensive surgery in debilitated patients or acute infection or hemorrhage may likewise induce acute adrenal failure and present itself as shock.In the course of routine neurosurgical . . .